- ResMed (NYSE:RMD +4%) FQ4 results: Revenues: $453.1M (+9.1%); COGS: $188.6M (+22.5%); R&D Expense: $28.5M (-10.4%); SG&A: $123.3M (+0.9%); Operating Income: $99.5M (+1.0%); Net Income: $87.5M (-0.2%); EPS: $0.61 (unch).
- FY2015 results: Revenues: $1,678.9M (+8.0%); COGS: $662.5M (+17.2%); R&D Expense: $114.9M (-2.8%); SG&A: $472.6M (+4.9%); Operating Income: $409.2M (+1.0%); Net Income: $352.9M (+2.2%); EPS: $2.47 (+3.3%); Quick Assets: $717.2M (-20.8%).
- No guidance given.